16773-51-6

Basic information

• Product Name: 2-methyl-4-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole
• Synonyms: 1H-Imidazole, 2-methyl-4-nitro-1- (oxiranylmethyl)-; 1H-imidazole, 2-methyl-4-nitro-1-(oxiranylmethyl)-; 2-Methyl-4-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole; Imidazole, 1- (2,3-epoxypropyl)-2-methyl-4-nitro-
• CAS NO: 16773-51-6
• Molecular Formula: C₇H₉N₃O₃
• Molecular Weight: 183.1647
• Mol File: 16773-51-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 395.5°C at 760 mmHg
• Flash Point: 193°C
• Density: 1.59g/cm³
• Vapor Pressure: 4.18E-06mmHg at 25°C
• Refractive Index: 1.684
• CAS DataBase Reference: 2-methyl-4-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl-4-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole(16773-51-6)
• EPA Substance Registry System: 2-methyl-4-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole(16773-51-6)

Safety Data

• Hazardous Substances Data: 16773-51-6(Hazardous Substances Data)

Usage

General Description

2-methyl-4-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole, also known as MNZ, is a chemical compound with a nitroimidazole structure. It is commonly used as an antiprotozoal and antibacterial agent, particularly in the treatment of infections caused by anaerobic bacteria and protozoa. MNZ is effective against a variety of parasitic infections, including giardiasis, trichomoniasis, and amoebiasis. It works by entering the cells of microorganisms and damaging their DNA, leading to their destruction. MNZ has also been investigated for its potential anti-cancer properties, as it has been shown to inhibit the growth of some cancer cells in laboratory studies. However, it is important to note that MNZ can have side effects, including nausea, vomiting, and dizziness, and should only be used under the supervision of a healthcare professional.

Upstream product

• 14419-11-5 (±)-1-chloro-3-(2-methyl-4-nitro-1H-imidazol-1-yl)propan-2-ol 

Relevant articles and documents

2-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study

Trichomoniasis is the most prevalent, non-viral sexually transmitted diseases (STD) caused by amitochondriate protozoan Trichomonas vaginalis. Increased resistance of T.?vaginalis to the marketed drug Metronidazole necessitates the development of newer chemical entities. A library of sixty 2-methyl-4/5-nitroimidazole derivatives was synthesized via nucleophilic ring opening reaction of epoxide and the efficacies against drug-susceptible and -resistant Trichomonas vaginalis were evaluated. All the molecules except two were found to be active against both susceptible and resistant strains with MICs ranging 8.55–336.70?μM and 28.80–1445.08?μM, respectively. Most of the compounds were remarkably more effective than the standard Metronidazole. This study analyzes the in?vitro and in?vivo activities of the new 5-nitroimidazoles, which were found to be safe against human cervical HeLa cells with good selectivity index. The exploration of SAR by the synthesis of four different prototypes and 3D-QSAR study has shown the importance of prototype 1 over other prototypes.

Synthesis and some physico-chemical properties of 1-(2-hydroxy-3-alkoxypropyl)-4-nitroimidazoles

-